Treatment of COVID-19-induced refractory status epilepticus by tocilizumab.
Eur J Neurol
; 29(9): 2861-2863, 2022 09.
Article
en En
| MEDLINE
| ID: mdl-35678591
ABSTRACT
BACKGROUND AND PURPOSE:
COVID-19 is a novel infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in which neurological complications have been increasingly recognized. Acute symptomatic epileptic seizures and status epilepticus are frequently reported neurological complications associated with this infection. The nervous system damage caused by SARS-CoV-2 may be mediated by the immune system. Interleukin 6 (IL-6), an important component of the cytokine storm, is directly correlated with the severity of symptoms. Tocilizumab is an inhibitor of IL-6 receptors, which blocks IL-6-mediated signal transduction and is used in the treatment of COVID-19 and status epilepticus. CASE REPORT A patient with the Unverricht-Lundborg disease is presented who had developed refractory recurrent status epilepticus during COVID-19 infection, which was finally controlled by treatment with tocilizumab.DISCUSSION:
Tocilizumab, an IL-6 inhibitor, may be considered as a treatment option in patients with status epilepticus and refractory seizures.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Estado Epiléptico
/
COVID-19
/
Tratamiento Farmacológico de COVID-19
Tipo de estudio:
Etiology_studies
Límite:
Humans
Idioma:
En
Revista:
Eur J Neurol
Asunto de la revista:
NEUROLOGIA
Año:
2022
Tipo del documento:
Article
País de afiliación:
Turquía